- Home
- DBVT vs JRS Comparison
DBVT vs JRS Comparison
Compare DBVT & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- JRS
- Stock Information
- Founded
- DBVT 2002
- JRS 2001
- Country
- DBVT France
- JRS United States
- Employees
- DBVT N/A
- JRS N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- JRS Finance/Investors Services
- Sector
- DBVT Health Care
- JRS Finance
- Exchange
- DBVT Nasdaq
- JRS Nasdaq
- Market Cap
- DBVT 260.5M
- JRS 231.7M
- IPO Year
- DBVT N/A
- JRS N/A
- Fundamental
- Price
- DBVT $15.48
- JRS $8.05
- Analyst Decision
- DBVT Buy
- JRS
- Analyst Count
- DBVT 4
- JRS 0
- Target Price
- DBVT $14.81
- JRS N/A
- AVG Volume (30 Days)
- DBVT 94.7K
- JRS 86.6K
- Earning Date
- DBVT 11-05-2025
- JRS 01-01-0001
- Dividend Yield
- DBVT N/A
- JRS 8.87%
- EPS Growth
- DBVT N/A
- JRS N/A
- EPS
- DBVT N/A
- JRS N/A
- Revenue
- DBVT $3,800,000.00
- JRS N/A
- Revenue This Year
- DBVT $1,743.46
- JRS N/A
- Revenue Next Year
- DBVT $1,044.34
- JRS N/A
- P/E Ratio
- DBVT N/A
- JRS N/A
- Revenue Growth
- DBVT N/A
- JRS N/A
- 52 Week Low
- DBVT $2.21
- JRS $5.95
- 52 Week High
- DBVT $15.95
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- DBVT 87.03
- JRS N/A
- Support Level
- DBVT $9.19
- JRS N/A
- Resistance Level
- DBVT $14.44
- JRS N/A
- Average True Range (ATR)
- DBVT 0.84
- JRS 0.00
- MACD
- DBVT 0.64
- JRS 0.00
- Stochastic Oscillator
- DBVT 100.00
- JRS 0.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.